ArticleOpen forum infectious diseases2022
Effectiveness of Dalbavancin Compared With Standard of Care for the Treatment of Osteomyelitis: A Real-world Analysis.
Article in Open forum infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06266494 (Prevention and Treatment of Frostbite Infection With Antimicrobial Pharmacokinetic Analysis), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prevention and Treatment of Frostbite Infection With Antimicrobial Pharmacokinetic Analysis
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Dalba Got Back? Use of Dalbavancin for the Treatment of Vertebral Osteomyelitis.Open forum infectious diseases · 2024Trial
- Optimizing Treatment of Infective Endocarditis in Patients Who Inject Drugs.Antibiotics (Basel, Switzerland) · 2026Review
- Off-label use of dalbavancin to improve treatment outcomes and reduce health care costs in people who use drugs: A Canadian single-centre quality improvement initiative.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2026Article
- Long-acting glycopeptides: what are the barriers to access in patients who need them most, and how can they be overcome?The Journal of antimicrobial chemotherapy · 2026Article
- Experience of use of dalbavancin for the treatment of unlicensed indications in a UK tertiary infectious diseases setting.Infection · 2025Article
- Budget Impact and Financial Analysis of Outpatient Dalbavancin in an Urban, Non-Teaching, Community Hospital.Clinical drug investigation · 2025Article
- Dalbavancin for Bone and Joint Infections: A Two-Center Greek Real-World Retrospective Study.Pathogens (Basel, Switzerland) · 2025Article
- Are Oritavancin and Dalbavancin More Cost Effective for Outpatient Parenteral Antimicrobial Therapy at a Veterans Affairs Medical Center?Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2025Article
- Addressing the Health Needs of People Who Inject Drugs: A Descriptive Analysis of an Inpatient Integrated Care Team Within an Acute Hospital in Scotland.Open forum infectious diseases · 2025Article
- Three-years of dalbavancin use at a UK tertiary referral hospital serving a population with high numbers of people who inject drugs.JAC-antimicrobial resistance · 2024Article
- New Frontier on Antimicrobial Therapy: Long-Acting Lipoglycopeptides.Pathogens (Basel, Switzerland) · 2024Review
- A Narrative Review on the Role of Dalbavancin in the Treatment of Bone and Joint Infections.Antibiotics (Basel, Switzerland) · 2023Review
- Dalbavancin in Bone and Joint Infections: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Kimyrsa and Orbactiv - A Tale of Two Formulations.Drug design, development and therapy · 2023Review
- From sea to shining IV: the current state of OPAT in the United States.Therapeutic advances in infectious diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPreliminary data suggest that the effectiveness of dalbavancin may be similar to current standard-of-care (SoC) treatment options for osteomyelitis with an advantageous dosing schedule.
methodsThis was a retrospective, observational cohort study of adult patients diagnosed with osteomyelitis. Patients were matched 1:2 to dalbavancin (administered as 2 doses separated by 1 week) or SoC treatment for osteomyelitis according to the Charlson Comorbidity Index, site of infection, and causative pathogen. The primary objective was to determine the incidence of treatment failure after a 1-year follow-up period. Secondary objectives included hospital length of stay (LOS), infection-related 1-year readmission rates, and treatment-related adverse events.
resultsA total of 132 patients received dalbavancin (n = 42) or SoC (n = 90). Baseline characteristics, including rates of surgical intervention, were similar between the 2 treatment groups. Treatment failure was similar between those who received dalbavancin and SoC (21.4% vs 23.3%;
conclusionsDalbavancin administered as a 2-dose regimen is a safe and effective option for the treatment of osteomyelitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.